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Abstract 37 
 38 
Vascular remodeling due to excessive proliferation of endothelial and smooth muscle cells is a 39 
hallmark feature of pulmonary hypertension. microRNAs (miRNAs) are a class of small, non-40 
coding RNA fragments that have recently been associated with remodeling of pulmonary 41 
arteries, in particular by silencing the bone morphogenetic protein receptor type II (BMPR2). 42 
Here we identified a novel pathway involving the concerted action of miR-125a, BMPR2 and 43 
cyclin-dependent kinase inhibitors (CDKN) that controls a proliferative phenotype of endothelial 44 
cells. An in silico approach predicted miR-125a to target BMPR2. Functional inhibition of miR-45 
125a resulted in increased proliferation of these cells, an effect that was found accompanied by 46 
upregulation of BMPR2 and reduced expression of the tumor suppressors CDKN1A (p21) and 47 
CDKN2A (p16). These data were confirmed in experimental pulmonary hypertension in vivo. 48 
Levels of miR-125a were elevated in lung tissue of hypoxic animals that develop pulmonary 49 
hypertension. In contrast, circulating levels of miR-125a were found to be lower in mice with 50 
pulmonary hypertension as compared to control mice. Similar findings were observed in a small 51 
cohort of patients with precapillary pulmonary hypertension. These translational data 52 
emphasize the pathogenetic role of miR-125a in pulmonary vascular remodeling. 53 
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Background 64 
 65 
Pulmonary hypertension (PH) is defined by an elevation of the mean pulmonary arterial 66 
pressure (mPAP) ≥ 25mmHg (1). This condition might be the consequence of several different 67 
entities as summarized in the clinical classification system of PH (2). The small pulmonary 68 
arteries in most of these diseases are characterized by vascular remodeling, i.e. by excessive 69 
proliferation of the vascular smooth muscle cell and endothelial layer resulting in increased 70 
vascular wall thickness and luminal occlusion.  71 
Many of these clinical disorders share one pathogenetic hallmark: genetic or non-genetic 72 
dysregulations of the bone morphogenetic protein receptor type II (BMPR2). This growth factor 73 
receptor has been found mutated in hereditary PAH (3), (4) and, in addition, downregulated in 74 
several other forms of the disease including PH due to congenital heart disease (5), (6), infection 75 
with the human immunodeficiency virus (7), hypoxia-induced PH (8) and in postcapillary 76 
elevation of the pulmonary pressure in heart failure patients (9). As evidenced in vitro and by 77 
therapeutic approaches in experimental models, the downregulation of BMPR2 might be due to 78 
the action of microRNAs (miRNAs) (10), (11), (12), which, moreover, have recently been 79 
associated with silencing of tumor suppressor genes and, as such, might further increase 80 
proliferation of vascular smooth muscle and endothelial cells. MiRNAs are endogenously 81 
expressed, non-coding RNA fragments of 18-22 nucleotides that bind to a complementary mRNA 82 
sequence of a target gene, a mechanism that inhibits further translation and results in post-83 
transcriptional gene silencing. MiRNAs have emerged in PH as important regulators in the 84 
pathogenesis of the pulmonary vascular remodeling, as therapeutic targets and, finally, as 85 
potential biomarkers.  86 
In this translational study, we conducted a screening for miRNAs that potentially interact with 87 
BMPR2 and identified altered expression of miR-125a in lung tissue samples of experimental PH. 88 
miR-125a was experimentally proven to regulate the expression of BMPR2 and the tumor 89 
suppressor CDKN1A in human endothelial cells resulting in a proproliferative phenotype of 90 
these cells. Levels of circulating miR-125a were further analyzed in experimental PH and in the 91 
serum of patients.  92 
 93 
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Materials and Methods 95 
 96 
Patients 97 
Recruitment of patients was performed from July 2012 to March 2013 during regular visits in 98 
our outpatient clinic. All patients with confirmed diagnosis of precapillary PH were asked to 99 
participate. 51 patients were included, 41 with PAH and 10 with CTEPH. Sample collection was 100 
made at any time point during follow up in our outpatient clinic unrelated to the latest right 101 
heart catheterization or echocardiography. Follow up and monitoring of patients was provided 102 
by regular visits in our outpatient clinic unrelated to the study design. Healthy adult control 103 
subjects were recruited from staff members at the University Hospital Zurich without matching 104 
between patients and control subjects. All patients gave their written informed consent. The 105 
study protocol was approved by Kantonale Ethikkommission (KEK) Zürich (approval number 106 
KEK–ZH–Nr 2010-0221). Table 1 summarizes characteristics of patients and healthy subjects. 107 
 108 
Blood sampling 109 
Peripheral venous blood samples were obtained from patients, who had precapillary PH 110 
confirmed by right-heart catheterization (patient clinical parameters, table 1), and from healthy 111 
control subjects. After clotting of blood, samples were centrifuged at 300g for 10 min and the 112 
supernatant (serum) was collected and stored at -80°C. 113 
 114 
Cell culture 115 
Human pulmonary artery smooth muscle cells (HPASMC) and human pulmonary artery 116 
endothelial cells (HPAEC) were obtained from Gibco (Life Technologies, Zug, Switzerland) and 117 
were cultured in supplemented medium 231 and supplemented medium 200 (both from Gibco), 118 
respectively. Cells were cultured at 37°C in a humidified atmosphere of 5% CO2. Exposure of 119 
cells to hypoxia was carried out at 37°C in a humidified atmosphere of 5% CO2 and 1% O2. 120 
 121 
Hypoxia-induced pulmonary hypertension 122 
Male mice (BL6) were obtained at the Institute for Veterinary Physiology at the University of 123 
Zurich. A total of 16 animals distributed equally in two groups consisting of one normoxic 124 
control and one hypoxic group (10% oxygen for 5 weeks). Hypoxic conditions were provided in 125 
chambers connected to a gas mixer (Ruskinn Life Science, Bridgend, United Kingdom). After 5 126 
weeks, mice were anesthetized and right heart catheterization was performed to measure the 127 
right ventricular pressure (RVP). In detail, a small skin incision was made in the neck of the mice 128 
and the right external jugular vein was isolated to insert a polyethylene (PE 10) catheter and 129 
forward it to the right ventricle of the heart. In each animal the blood pressure within the right 130 
ventricle was continuously recorded with a 1khz sampling frequency for at least 30 seconds 131 
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using a piezoelectric pressure transducer and the PowerLab system (ADInstruments, Spechbach, 132 
Germany). After recording a 500µl venous blood sample was drawn from the right ventricle via 133 
the catheter. After blood collection the animals were euthanized by cervical dislocation and 134 
lungs were collected. To isolate miRNAs from lung tissue samples, the miRNeasy Mini kit 135 
(Qiagen, Hombrechtikon, Switzerland) was used. Circulating miRNAs from murine plasma were 136 
purified as described in the section of purification of circulating miRNAs. All animal experiments 137 
were approved by the Swiss Cantonal Veterinary Office (license 151/2012, Zurich, Switzerland) 138 
 139 
Purification of circulating miRNAs 140 
MiRNAs were purified from human serum or murine plasma as described before (13). Briefly, 141 
100µl of plasma and 600µl of serum were denatured by the addition of 400µl and 1200µl of 142 
Qiazol (Qiagen), respectively. To control technical variabilities during RNA isolation procedure 143 
and since no specific miRNAs are recommended to serve as suitable endogenous control, 144 
synthetic Caenorhabditis elegans miRs, cel-miR-39 and cel-miR-238 (synthesized by Microsynth, 145 
Balgach, Switzerland) were added to the denatured sample (10µl of a 5fmol solution) and used 146 
as described in Kroh et al (13). After centrifugation (12.000g at 4°C for 15min) supernatants 147 
were mixed with ethanol and transferred to miRNeasy spin columns (Qiagen). RNA samples 148 
containing miRNAs were eluted in 32µl RNAse-free water and stored at -20°C. 149 
 150 
Quantification of mature miRNAs 151 
Mature miRNA sequences were detected with specific stem-loop primers and reverse 152 
transcribed using MultiScribe reverse transcriptase (Life Technologies, Zug, Switzerland) 153 
according to Chen et al (14). Quantification of complementary DNA (cDNA) was performed by 154 
SYBR Green quantitative PCR (qPCR, Applied Biosystem StepOnePlus system, Life Technologies). 155 
The reverse transcription (RT) and amplification primers used in this study are shown in table 2 156 
To enhance sensitivity cDNA samples of murine plasma were pre-amplified prior qPCR analysis 157 
(13). Briefly, cDNA samples were mixed with the respective miRNA-specific forward primer and 158 
the universal reverse primer and were amplified with Phire polymerase (Thermo Scientific, 159 
Wohlen, Switzerland) for 14 cycles. qPCR data of circulating miRNAs were median-normalized 160 
to the mean cycle of threshold (ct) values of the spike-in controls, cel-miR-39 and cel-miR-238, 161 
and expressed as median-normalized ct values as recommended by Kroh et al (13). Median-162 
normalized instead of absolute levels were used to control technical variabilities during RNA 163 
isolation.  164 
Obtained qPCR data of miRNAs derived from murine lung tissue and cultured human cells were 165 
normalized to the endogenous control snoRNA202 and RNU48, respectively. Differential miRNA 166 
expression was calculated with the Δct method (15). Specific PCR amplification was confirmed 167 
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by performing dissociation curve analysis. Moreover, correct amplification of cel-miR-39, cel-168 
miR-238, and miR-125a was confirmed by using DNA sequencing reaction (Microsynth).   169 
 170 
Transient transfection of primary cultured cells 171 
For manipulation of endogenous levels of miR-125a, HPASMC and HPAEC were transfected with 172 
anti-miR-125a or scrambled negative control (both 25nM) using Lipofectamine 2000 (Life 173 
Technologies). Methylated oligonucleotides (anti-miR-125a: 5’ - UCA CAG GUU AAA GGG UCU 174 
CAG GGA – 3’; and scrambled negative control: 5’ – GAC CGU UCA CUA UUA CGA GUC AA – 3’) 175 
were synthesized at Microsynth. Following an incubation period of 72h cells were harvested and 176 
gene expression analysis was performed.  177 
 178 
Quantitative real time-PCR (qPCR) analysis 179 
Total RNA of cultured cells or murine lung tissue samples was purified using the miRNeasy kit 180 
(Qiagen). Isolated RNA was reverse transcribed by using random hexamers and MultiScribe 181 
reverse transcriptase (both from Life Technologies). Quantification of specific gene transcripts 182 
was performed by SYBR Green qPCR (Applied Biosystem StepOnePlus system, Life 183 
Technologies). Sequences of primers used in this study are shown in the table 2. Specific 184 
amplification was verified by performing melt curve analysis. Obtained expression levels of 185 
genes of interest were normalized to the expression of β-actin. Differential gene expression was 186 
calculated with the threshold cycle (ct) method (15). 187 
 188 
Western blotting 189 
For protein extraction, harvested cells were lysed with sample loading buffer (62.5mM Tris-HCl, 190 
pH 6.8, 2% SDS, 10% glycerol, 5mM β-mercaptoethanol, bromphenolblue). Whole-cell lysates 191 
were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 192 
the proteins were transferred to nitrocellulose membrane (Whatman, GE Healthcare Life 193 
Sciences, Little Chalfont, UK). Membranes were incubated with the following primary 194 
antibodies: anti – BMPR2 (mouse antibody, ab78422, Abcam plc, Cambridge, UK), anti-CDKN1A 195 
(rabbit antibody, #2947 Cell Signaling Technologies, Danvers, MA, USA), anti-CDKN2A (rabbit 196 
antibody, ab108349, Abcam plc, Cambridge, UK) and anti – β-actin (mouse antibody, #A2228, 197 
Sigma-Aldrich, Buchs SG, Switzerland). Bands were detected with species-specific secondary 198 
antibodies coupled to horseradish peroxidase (Jackson ImmunoResearch Europe Ltd, Suffolk, 199 
UK). Calculation of the expression of proteins was performed using Adobe Photoshop CS5.1 200 
software (Adobe Systems Incorporated, San Jose, CA, USA) via pixel quantification of the 201 
electronic image.  202 
 203 
 204 
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Proliferation assay 205 
To assess the proliferation rate, HPASMC and HPAEC were seeded in 96-well plates and were 206 
transfected with 25nM of anti-miRNAs (scrambled negative control or anti-miR-125a) using 207 
Lipofectamine 2000 (Life Technologies). After 48h, 5-bromo-2-deoxy-uridine (BrdU) was added 208 
to each well and incubated for 24h. Incorporation of BrdU was detected using the colorimetric 209 
BrdU assay from Roche (Roche Diagnostics, Mannheim, Germany) and spectrophotometrically 210 
measured at a test wavelength of 450nm (reference wavelength: 620nm). The measured 211 
absorbance directly correlates with the proliferation and the number of cells. 212 
 213 
Statistics 214 
For statistical analysis GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA) 215 
was used. Values are presented as mean ± standard deviation. Parametric or non-parametric 216 
distribution of data was determined using the Kolmogorov-Smirnov test. Data comparison was 217 
performed using independent Student’s t-test as well as Pearson’s correlation for parametric 218 
samples and Mann-Whitney test for non-parametric samples. For statistical analysis of multiple 219 
groups the 1way analysis of variance with Bonferroni post hoc test was used. A p-value < 0.05 220 
was considered significant (* p<0.05, ** p<0.01, *** p<0.001). In all statistical analyses, two sided 221 
tests were applied. The n number indicates independent experiments. Each experiment was 222 
measured in duplicates. 223 
 224 
225 
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Results 226 
Hypoxia induces miR-125a in vivo and in vitro 227 
A computational target screen was performed (TargetScan, www.targetscan.org) and identified 228 
several miRNAs that potentially interact with the 3’ untranslated region (3’UTR) of BMPR2 (data 229 
not shown). Since a strong interaction was predicted for miR-125a, screening for the expression 230 
of this miRNA was performed in lung tissue samples of animals, in which pulmonary 231 
hypertension was induced by hypoxia and in human pulmonary vascular cells.  232 
As shown in Figure 1A, animals exposed to hypoxia (10% oxygen for 5 weeks) developed 233 
significantly higher right ventricular pressure as their normoxic controls (45.45±3.63mm Hg vs. 234 
30.83±2.56mm Hg, p<0.001). Expression levels of miR-125a were analyzed in lung tissue and 235 
were found to be significantly upregulated (by 73%) in mice with PH as compared to control 236 
mice (in ct values normalized to snoRNA202. Higher ct values indicate lower abundance of the 237 
miRNA of interest: 2.09±0.42 vs. 2.88±0.19, p<0.001, Fig. 1B). Next, we assessed the effect of 238 
oxygen deprivation on distinct pulmonary vascular cells by using HPAEC and HPASMC. Baseline 239 
expression levels of miR-125a were found to be 2.5-fold higher in HPAEC than in HPASCM (in ct 240 
values normalized to RNU48: 1.54±0.54 vs. 2.86±0.25, p<0.01, Fig. 1C). Hypoxic conditions 241 
further induced the levels of miR-125a in HPAEC significantly (by 1.4-fold after 24h of hypoxia, 242 
Fig. 1D). Conversely, levels of miR-125a in HPASMC were unchanged by hypoxic conditions (Fig. 243 
1E).  244 
 245 
The expression of BMPR2 is regulated by miR-125a in human endothelial cells 246 
miR-125a is predicted to bind to and regulate the expression of BMPR2 (according to miRNA 247 
prediction software TargetScan). To confirm this interaction, the endogenous expression of miR-248 
125a in HPAEC and HPASMC was silenced by transfection of anti-miR-125a oligonucleotides and 249 
expression levels of BMPR2 were analyzed. As measured by qPCR, transfection of HPAEC with 250 
anti-miR-125a significantly reduced the expression of miR-125a when compared to scrambled 251 
transfected cells (by 67.8±9.5%, p<0.01, Fig. 2A). Silencing of miR-125a increased the mRNA 252 
levels of BMPR2 without reaching statistical significance in HPAEC (Fig. 2B). Of interest, protein 253 
levels of BMPR2 were found significantly upregulated when the expression of miR-125a was 254 
antagonized (from 0.82±0.23 to 1.27±0.37, p=0.031, normalized toβ-actin expression, Fig. 2C) 255 
indicating a posttranscriptional mechanism of action.    256 
In HPASMC, the expression of miR-125a was strongly reduced upon transfection of anti-miR 257 
oligonucleotides as measured by qPCR (by 98.3±2.4% p<0.001, Fig. 2D). In contrast to HPAEC, 258 
treatment of HPASMC with anti-miR-125a failed to modulate the expression levels of BMPR2 on 259 
the mRNA (Fig. 2E) as well as on the protein level (Fig. 2F).  260 
These data demonstrate that BMPR2 is targeted by miR-125a in HPAEC but not in HPASMC.  261 
 262 
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miR-125a regulates  the proliferation of HPAEC  263 
Our group recently demonstrated that an upregulation of BMPR2 in vascular cells inhibited cell 264 
proliferation probably by induction of cyclin-dependent kinase inhibitor 1A (CDKN1A) (12). To 265 
test whether miR-125a modulates cell proliferation in a similar way, HPAEC and HPASMC were 266 
transfected with anti-miR-125a oligonucleotides and BrdU incorporation assays were 267 
performed. Moreover, the mRNA levels of all relevant CDK inhibitors (CDKN1A/-1B/-1C/-2A/-268 
2B/-2C and -2D) were measured by qPCR. As presented in Figure 3A, silencing of miR-125a 269 
significantly decreased the proliferation rate of HPAEC when compared to negative control cells 270 
(in absorbance units measured at a test wavelength of 450nm: from 0.42±0.07 to 0.28±0.07, 271 
p<0.01). Of interest, levels of the most abundantly expressed CDK inhibitors, CDKN1A and 272 
CDKN2A, were found significantly increased when miR-125a was silenced (Fig. 3B). These data, 273 
at least for CDKN1A, were confirmed on protein level by Western blotting and densitometric 274 
analysis (Fig. 3C). 275 
In HPASMC, transfection with anti-miR-125a did not change the proliferation rate (Fig. 4A). 276 
Along that line, inhibition of miR-125a in HPASMC failed to increase the levels of CDKN1A 277 
whereas a significant decrease of mRNA levels of CDKN2A was observed (Fig. 4B). Protein levels 278 
of CDKNA1 and CDKNA2 were significantly decreased after antagonizing miR-125a (Fig. 4C). 279 
These data imply that inhibition of miR-125a represses proliferation of HPAEC via upregulation 280 
of CDKN1A and CDKN2A. In HPASMC this mechanism was not observed, implying a differential 281 
regulation of miR-125a in these two cell types.  282 
 283 
Hypoxia-induced expression of miR-125a correlates with downregulation of BMPR2 and 284 
CDKN1A in vivo 285 
The regulation of BMPR2 and CDKN1A by miR-125a was further characterized in lung samples 286 
of the mouse model of hypoxia-induced PH (same samples as in Figure 1B). As presented in 287 
Figure 5a, chronic exposure to hypoxia significantly reduced the mRNA expression of BMPR2 (in 288 
Δct values: control mice 3.91±0.29 vs. mice with PH 4.35±0.36, p=0.028; indicating a reduction 289 
of 26%) and of CDKN1A (control mice 4.26±0.47 vs. mice with PH 5.68±0.36, p<0.001; indicating 290 
a reduction of 62%). Since the levels of miR-125a were significantly increased in hypoxic lungs 291 
(shown in Fig. 1B), a correlation analysis was performed (Figure 5B) showing a significant 292 
inverse correlation of miR-125a with BMPR2 (r=-0.629, p<0.01) as well as with CDKN1A 293 
(r=-0.563, p=0.023).  294 
These data indicate that miR-125a regulates the expression of BMPR2 and CDKN1A in vivo. Thus 295 
miR-125a appears to have a functional role in pulmonary artery remodeling that involves 296 
regulation of BMPR2 and the tumor suppressor genes CDKN1A and CDKN2A in cells of the 297 
endothelial layer. 298 
 299 
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Circulating miR-125a in experimental and human precapillary pulmonary hypertension 300 
Plasma samples of mice with PH showed a significant reduction (by 43%) of the levels of 301 
circulating miR-125a as compared to control mice (25.76±0.81 vs. 24.94±0.56, p=0.035, Fig. 6A). 302 
These data were confirmed by analysing the expression levels of miR-125a in patients (n=51) in 303 
which the diagnosis of precapillary PH has been made by right heart catheterization (Fig. 6B). 304 
Circulating levels of miR-125a were found to be significantly reduced (by 52%) in patients as 305 
compared to controls (28.68±1.2 vs. 27.62±1.15, p<0.001). Lower expression levels of miR-125a 306 
were found in both subgroups of patients, i.e. in patients with PAH (28.65±1.28 vs. 27.62±1.15, 307 
p<0.001, reduction of 51%) and in patients with PH due to chronic thromboembolic events 308 
(28.78±0.87 vs. 27.62±1.15, reduction of 55%) when compared to the expression level of control 309 
subjects.  310 
 311 
312 
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Discussion 313 
In this translational study we identified BMPR2 as a novel target of miR-125. Inhibition of miR-314 
125a resulted in reduced proliferation of HPAEC in vitro, an effect probably mediated by direct 315 
interaction of miR-125a with BMPR2 and indirect involvement of the tumor suppressors 316 
CDKN1A and CDKN2A. These data are supported by findings from an experimental model of PH, 317 
in which hypoxic animals with PH showed higher expression levels of miR-125a in lung tissue 318 
compared to normoxic control mice. Of note, however, lower circulating levels of miR-125a were 319 
found in experimental PH. These results were confirmed in a small cohort of human samples 320 
showing that the levels of miR-125a are significantly lower in the serum of patients with 321 
precapillary PH as compared to healthy control subjects.  322 
 323 
By computational screening we identified several miRNAs to interact with BMPR2, the most 324 
important mediator of vascular remodeling in PH. Functional in vitro experiments confirmed 325 
that inhibition of miR-125a by addition of anti-miRs increased the expression of BMPR2, 326 
whereas proliferation of HPAEC was found to be reduced implicating a role of miR-125a in 327 
vascular remodeling. Our data provide no experimental prove for a direct interaction between 328 
miR-125a and BMPR2 but confirm this correlation.  Of note, the pro-proliferative effects of miR-329 
125a were found to be associated with decreased expression of the tumor suppressors CDKN1A 330 
and CDKN2A, which represent major control factors in the regulation of cell cycle. CDKN1A and 331 
2A were found upregulated following treatment with anti-miRs directed against miR-125a in 332 
HPAEC. Since both CDKN1A/ 2A have not been predicted as targets of miR-125a by a 333 
computational approach, we suggest that this upregulation is the consequence of an indirect 334 
effect of miR-125a probably mediated by downstream signalling of BMPR2. Such downstream 335 
effects on CDKN1A have already been implicated by stimulation experiments with BMP-2 in 336 
tumor cells (16) and by a previous study in which functional levels of BMPR2 were restored in 337 
an in vivo model for pulmonary hypertension by treatment with antagomiRs (12) . 338 
 339 
Depending on type and context of different cells, the miR-125 family has been implicated in 340 
several mechanisms including inflammation, cell growth, differentiation and metastasis 341 
(reviewed in (17)). Moreover, the miR-125 family has been associated with the signal 342 
transducer and activator of transcription (STAT)-3 (18), which, directly (10) or through the 343 
action of NFAT-1 (19), has also been implicated in the context of vascular remodeling in PH. In 344 
our experiments performed in pulmonary artery endothelial cells, inhibition of miR-125a 345 
decreased proliferation whereas no effects have been observed in vascular smooth muscle cells. 346 
Conversely, a recent study has described that antagonization of miR-125 has proliferative effects 347 
in HUVECs and suggested to reduced levels of miR-125a might have a proangiogenic effect (20). 348 
These controverse findings are not completely explained, but paradoxical reactions of the 349 
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pulmonary vasculature in response to hypoxia as compared to systemic vessels are a well-350 
known phenomenon. Moreover, dysfunctional angiogenesis is an important feature in 351 
pulmonary arterial hypertension despite it is considered to be a proangiogenic disease (21) 352 
However, the differential effects of miR-125a on BMPR2 expression and proliferation of 353 
endothelial and smooth muscle cells is a novel observation. The mechanisms of these effects are 354 
not completely clear but might be explained by the differential baseline expression and a 355 
different behaviour of miR-125a upon oxygen deprivation in these cells. Data from an 356 
experimental model confirmed that hypoxia activates the expression of miR-125a in lung tissue 357 
of mice, i.e. mice with PH showed significantly higher levels of miR-125a in lung tissue as control 358 
animals. Along the line of the in vitro data, the increased levels of miR-125a were associated with 359 
reduced expression of BMPR2 and CDKN1A and, as such, highlight the relevance of the identified 360 
pathway in vivo. 361 
 362 
Finally, we assessed the levels of miR-125a in the circulation of both animals and patients. Of 363 
interest, we found lower circulating levels of miR-125a in mice with PH as compared to 364 
normoxic controls.  This might be unexpected at a first glance. However, we suggest that the low 365 
circulating levels of miR-125a are the consequence of high intracellular activity of miR-125a. 366 
This intracellular activity, as predicted from computational studies and supported by our in vitro 367 
experiments, might reflect the interaction between miR-125a and BMPR2 in endothelial cells. 368 
Alternatively, the low circulating levels of miR-125a might be the consequence of the previously 369 
described dysregulated expression of DICER in patients with PH (22). Data from a small and 370 
heterogeneous collective of patients with pulmonary arterial hypertension confirmed the 371 
experimental findings by showing that the expression of miR-125a is most significantly 372 
downregulated in the serum of patients as compared to the levels of healthy controls.  At the 373 
moment it remains unclear, however, whether decreased expression levels of miR-125a 374 
contribute to progression of the disease and, as such, are of prognostic value or, alternatively, 375 
whether low levels of miR-125a are a consequence of hypoxic conditions observed in patients 376 
with PH. Our data are further limited by the lack of data on pharmacological inhibition of miR-377 
125a which precludes conclusions on the clinical relevance. 378 
 379 
Conclusions 380 
In conclusion, these data describe a novel pathway involving miR-125a, BMPR2 and CDKN1A, 381 
which regulates a proproliferative phenotype of pulmonary endothelial cells. This pathway 382 
appears to be specific for endothelial cells. This is of particular interest since reduced expression 383 
levels of circulating miR-125a are found in experimental PH and in patients with precapillary PH 384 
as compared to healthy controls.  385 
 386 
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BMPR2 = bone morphogenetic protein receptor, type II 388 
BrdU = 5-bromo-2-deoxy-uridine  389 
CDKN = cyclin-dependent kinase inhibitor 390 
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HPASMC = human pulmonary artery smooth muscle cells   394 
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Figure legends 496 
 497 
Figure 1. Hypoxia induces miR-125a in vivo and in vitro 498 
A) Animals exposed to hypoxia (10% oxygen for 5 weeks) developed significantly higher right 499 
ventricular pressure as their normoxic controls (n=8 each). B) Expression levels of miR-125a in 500 
lung tissue were found to be significantly upregulated in mice with PH as compared to control 501 
mice as analyzed by qPCR. C) Baseline expression levels of miR-125a were found to be higher in 502 
HPAEC than in HPASCM as shown by qPCR analysis. D) Hypoxia (1% oxygen) increased the 503 
levels of miR-125a in HPAEC significantly (n=6), whereas E) the levels of miR-125a in HPASMC 504 
were unchanged by hypoxic conditions (n=3). Statistical analysis by unpaired Student’s t-test 505 
and 1way analysis of variance with Bonferroni post hoc test (*p<0.05, ** p<0.01, ***p<0.001). 506 
 507 
Figure 2. miR-125a targets BMPR2 in human pulmonary artery endothelial cells  508 
A) Addition of anti-miRs directed against miR-125a significantly decreased the levels of miR-509 
125a in cultured HPAEC (n=6). B) As shown by qPCR analysis inhibition of miR-125a slightly 510 
upregulated the mRNA levels of BMPR2 in HPAEC when compared to scrambled transfected 511 
cells (n=6). C) Protein levels of BMPR2 were found significantly increased in anti-miR-125a 512 
transfected HPAEC (n=6). A representative western blot is shown. D) Transfection of HPASMC 513 
with anti-miR-125a significantly repressed the levels of miR-125a (n=6) but E) did not change 514 
the expression of BMPR2 on the mRNA (n=6) as well as F) on the protein level (n=4). A 515 
representative Western Blot is provided. Statistical analysis by unpaired Student’s t-test 516 
(*p<0.05, **p<0.01, ***p<0.001). 517 
 518 
Figure 3. miR-125a regulates the expression of cyclin-dependent genes and modulates 519 
endothelial cell proliferation.  520 
A) As assessed by BrdU incorporation assay, the antagonization of miR-125a significantly 521 
reduced the proliferation rate of HPAEC (n=6). B) The mRNA levels of all relevant CDK inhibitors 522 
were measured in HPAEC by qPCR showing a significant increase of the expression of CDKN1A 523 
and CDKN2A after treatment with anti-miR-125a when compared to scrambled transfected cells 524 
(n=6). C) A representative Western Blot and densitometric analysis is provided. Statistical 525 
analysis by unpaired Student’s t-test (*p<0.05, **p<0.01). 526 
 527 
Figure 4. miR-125a has no effect on the proliferation of smooth muscle cells.  528 
A) In HPASMC, the inhibition of miR-125a did not change the proliferation rate as demonstrated 529 
by BrdU incorporation assay (n=9). B) A significant decrease of the mRNA expression of 530 
CDKN2A was found in anti-miR-125a transfected HPASMC (n=6).  C) A representative Western 531 
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Blot and densitometric analysis is provided. Statistical analysis by unpaired Student’s t-test 532 
(**p<0.01). 533 
 534 
Figure 5. Hypoxia-induced expression of miR-125a correlates with downregulation of 535 
BMPR2 and CDKN1A in vivo. A) The expression of BMPR2 and CDKN1A was measured by qPCR 536 
in lung tissue samples obtained from mice that developed PH after chronic exposure to hypoxia 537 
(same samples as in Fig. 1B). When compared to normoxic samples, a significant decrease of the 538 
mRNA expression of BMPR2 and CDKN1A was observed (n=8). B) A significant inverse 539 
correlation was found when the expression of miR-125a was compared to the levels of BMPR2 540 
and CDKN1A in lungs of mice with PH (n=8). Statistical analysis by unpaired Student’s t-test, 541 
Pearson’s correlation, and Mann-Whitney test (*p<0.05, ***p<0.001).  542 
 543 
Figure 6. miR-125a in experimental and human pulmonary hypertension.  544 
A) Plasma levels of circulating miR-125a were significantly reduced in mice with PH as 545 
compared to control mice as shown by qPCR analysis (n=8 each). B) Serum levels of miR-125a 546 
are significantly lower in patients with precapillary pulmonary hypertension (second from left, 547 
n=51) as compared to healthy controls (left, n=41). This trend is confirmed by analysis of clinical 548 
subgroups including 41 patients with pulmonary arterial hypertension (group 1, third from left) 549 
and in 10 patients with pulmonary hypertension due to chronic thromboembolic events (group 550 
4, right). Statistical analysis by unpaired Student’s t-test and 1way analysis of variance with 551 
Bonferroni post hoc test ((*p<0.05, ***p<0.001). 552 
 553 
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Table 1. Patients’ characteristics 
 
 patients controls 
number 51 41 
female:male 35:16 22:19 
 
PAH 
-idiopathic/ hereditary PAH 
 
41 
29 
 
-collagen-vascular diseases 7  
-congenital heart diseases 5  
CTEPH 
PH target therapy* 
- Endothelin-Receptor-
Antagonists 
- Phosphodiesterase-5-Inhibitors 
- Prostacyclines** 
10 
 
44 
 
22 
9 
 
 
* several patients are treated with combination therapy 
** intravenous epoprostenol (2 patients), inhalative iloprost (4 patients), subcutanous treprostinil (3 patients) 
 
Table 2. Primer sequences 
 
miRNA expression primer  
miR-125a RT (hsa, mmu)  5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACT CAC AG – 3’
miR-125a fwd (hsa, mmu) 5’ – TCC CTG AGA CCC TTT AAC C – 3’ 
cel-miR-39 RT 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC AAG CT - 3’
cel-miR-39 fwd 5’- CCT CAC CGG GTG TAA ATC AG - 3’ 
cel-miR-238 RT 5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACT CTG AA - 3’ 
cel-miR-238 fwd 5’- CTT TGT ACT CCG ATG CCA TTC - 3’
snoRNA202 RT (mmu) 5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC ATC AG – 3’ 
snoRNA202 (mmu) fwd 5’ – CCG TAC TTT TGA ACC CTT TTC – 3’ 
RNU48 RT (hsa) 5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACG GTC AG – 3’
RNU48 (hsa) fwd 5’ – CCA TGA GTG TGT CGC TGA TG – 3’ 
universal reverse primer 5’ - GAG GTA TTC GCA CTG GAT AC - 3’
gene expression primer  
β-actin fwd (hsa, mmu)  5’ – TCA AGA TCA TTG CTC CTC CTG AG – 3’
β-actin rev (hsa, mmu)  5’ – TCC TGC TTG CTG ATC CAC ATC – 3’ 
BMPR2 fwd (hsa) 5’ – AGC CCA ACA GTC AAT CCA ATG – 3’
BMPR2 rev (hsa)  5’ – GGT TGC GTT CAT TCT GCA TAG – 3’ 
CDKN1A fwd (hsa) 5’ - AGC ATG ACA GAT TTC TAC CAC TC – 3’ 
CDKN1A rev (hsa) 5’ - GGC TTC CTC TTG GAG AAG ATC – 3’
CDKN1B fwd (hsa) 5’ - ACC TGC AAC CGA CGA TTC TTC - 3’ 
CDKN1B rev (hsa) 5’ - CAT TTG GGG AAC CGT CTG AAA C - 3’ 
CDKN1C fwd (hsa) 5’ - CCT CTG ATC TCC GAT TTC TTC - 3’
CDKN1C rev (hsa) 5’ - ACT TCT CAG GCG CTG ATC TC - 3’
CDKN2A fwd (hsa) 5’ - CTC AGA CAT CCC CGA TTG AAA G - 3’
CDKN2A rev (hsa) 5’ - CTT CGG TGA CTG ATG ATC TAA G - 3’
CDKN2B fwd (hsa) 5’ - TCA CCA TGA AGC GAA ACA CAG - 3’
CDKN2B rev (hsa) 5’ - GAA AAC CCT GAA AAG CAA ACG AC - 3’
CDKN2C fwd (hsa) 5’ - CGC TGC AGG TTA TGA AAC TTG - 3’
CDKN2C rev (hsa) 5’ - GGG ATT AGC ACC TCT AAG TAG - 3’ 
CDKN2D fwd (hsa) 5’ - CGC TGC AGG TCA TGA TGT TTG - 3’ 
CDKN2D rev (hsa) 5’ - GTC ATG GAC TGG ACT GGT AC - 3’ 
 
